Compare EXP & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EXP | PCVX |
|---|---|---|
| Founded | 1963 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 7.0B |
| IPO Year | 1994 | 2020 |
| Metric | EXP | PCVX |
|---|---|---|
| Price | $216.82 | $47.28 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 4 |
| Target Price | ★ $227.11 | $88.25 |
| AVG Volume (30 Days) | 393.7K | ★ 1.4M |
| Earning Date | 05-19-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.49% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 13.16 | N/A |
| Revenue | ★ $495,023,000.00 | N/A |
| Revenue This Year | $1.97 | N/A |
| Revenue Next Year | $1.95 | N/A |
| P/E Ratio | $16.20 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $171.99 | $29.10 |
| 52 Week High | $243.64 | $65.00 |
| Indicator | EXP | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 55.96 | 41.44 |
| Support Level | $202.60 | $46.39 |
| Resistance Level | $224.61 | $49.46 |
| Average True Range (ATR) | 6.97 | 1.94 |
| MACD | -0.03 | 0.03 |
| Stochastic Oscillator | 64.92 | 30.30 |
Eagle Materials Inc produces and sells construction products and building materials. Construction products include cement, slag, concrete, and aggregates and building materials include cement and gypsum wallboard, and are sold to the construction and building industries. The firm organizes itself into two sectors: Heavy Materials, which includes the Cement and Concrete and Aggregates segments, and Light Materials, which includes the Gypsum Wallboard and Recycled Paperboard segments.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.